Triple negative breast cancer - prognostic factors and survival

Gluz O, Liedtke C, Gottschalk N, Pustzai L, Nitz U, Harbeck N. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-27.10.1093/annonc/mdp492Search in Google Scholar

Podkrajšek M, Žgajnar J, Hočevar M. What is the most common mammographic appearance of T1a and T1b inasive breast cancer? Radiol Oncol 2008; 42: 173-80.10.2478/v10019-008-0018-0Search in Google Scholar

Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: Clinical and prognostic implications. Eur J Cancer 2009; 45: 27-40.10.1016/S0959-8049(09)70013-9Search in Google Scholar

Anders KC, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009; 9(Suppl 2): S73-81.10.3816/CBC.2009.s.008Search in Google Scholar

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-1010.1111/j.1365-2559.1991.tb00229.xSearch in Google Scholar

Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-44.10.1016/S1470-2045(07)70074-8Search in Google Scholar

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway KS, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.10.1001/jama.295.21.249216757721Search in Google Scholar

Debevec L, Jeric T, Kovac V, Bitenc M, Sok M. Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol 2009; 43: 47-53.10.2478/v10019-009-0008-xSearch in Google Scholar

Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 2008; 31: 610-4.Search in Google Scholar

Shibuta K, Ueo H, Furusawa H, Komaki K, Rai Y, Sagar Y, et al. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4266 Japanese women with breast cancer. Breast Cancer 2010; Jun 23. [Epub ahead of print]. DOI: 10.1007/s12282-010-0209-6.10.1007/s12282-010-0209-620571962Search in Google Scholar

Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008; 15: 303-8.10.1007/s12282-008-0042-318369692Search in Google Scholar

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.10.1158/1078-0432.CCR-06-304517671126Search in Google Scholar

Plesnicar A, Golicnik M, Fazarinc IK, Kralj B, Kovac V, Plesnicar BK. Attitudes of midwifery students towards teaching breast-self examination. Radiol Oncol 2010; 44: 52-6.10.2478/v10019-010-0009-9342367122933891Search in Google Scholar

Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, et al. Invasive ductal carcinoma of the breast with "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116: 317-28.10.1007/s10549-008-0206-z18839307Search in Google Scholar

Liedke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275-81.10.1200/JCO.2007.14.414718250347Search in Google Scholar

Lin NU, Vanderplas A, Hughes ME, Theriault R L, Edge SB, Wong Y, et al. Clinopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). [Abstract]. J Clin Oncol 2009; 27(15 Suppl): Abstract 543.10.1200/jco.2009.27.15_suppl.543Search in Google Scholar

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, et al. Prognostic impact of clinicopathological parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 2007; 7: 203.10.1186/1471-2407-7-203221755817976237Search in Google Scholar

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-34.10.1158/1078-0432.CCR-06-110917438091Search in Google Scholar

Tutt A, Robson M, Garber JE, Domchek S. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. [Abstract]. J Clin Oncol 2009; 27(Suppl 18): 803s.10.1200/jco.2009.27.18_suppl.cra501Search in Google Scholar

O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. [Abstract]. J Clin Oncol 2009; 27(Suppl 18): 793s.10.1200/jco.2009.27.18_suppl.3Search in Google Scholar